# *Parva* Cas9-CKO Strategy

Designer: Lingyan Wu

Reviewer: Jiayuan Yao

Design Date: 2020-4-16

# Project Overview

| | |
|---|---|
| **Project Name** | ***Parva*** |
| **Project type** | **Cas9-CKO** |
| **Strain background** | **C57BL/6J** |

# Conditional Knockout strategy

This model will use CRISPR/Cas9 technology to edit the *Parva* gene. The schematic diagram is as follows:



# Technical routes

- The *Parva* gene has 5 transcripts. According to the structure of *Parva* gene, exon2-exon3 of *Parva-201* (ENSMUST00000033030.13) transcript is recommended as the knockout region.The region contains 161bp coding sequence. Knock out the region will result in disruption of protein function.

- In this project we use CRISPR/Cas9 technology to modify *Parva* gene. The brief process is as follows:CRISPR/Cas9 system and Donor were microinjected into the fertilized eggs of C57BL/6J mice.Fertilized eggs were transplanted to obtain positive F0 mice which were confirmed by PCR and sequencing. A stable F1 generation mouse model was obtained by mating positive F0 generation mice with C57BL/6J mice.

- The flox mice will be knocked out after mating with mice expressing Cre recombinase, resulting in the loss of function of the target gene in specific tissues and cell types.

# Notice

- According to the existing MGI data,embryos homozygous for a null allele are growth retarded and die prior to e14.5 exhibiting abnormal cardiac morphogenesis, severe vascular defects, edema, microaneurysms, hemorrhage, and severe kidney dysgenesis or agenesis.
- The *Parva* gene is located on the Chr7. If the knockout mice are crossed with other mice strains to obtain double gene positive homozygous mouse offspring, please avoid the two genes on the same chromosome.
- This strategy is designed based on genetic information in existing databases.Due to the complexity of biological processes, all risk of loxp insertion on gene transcription, RNA splicing and protein translation cannot be predicted at existing technological level.

# Gene information （NCBI）

集萃药康 GemPharmatech

## Parva parvin, alpha [Mus musculus (house mouse)]

Gene ID: 57342, updated on 13-Mar-2020

### Summary

| | |
|---|---|
| **Official Symbol** | Parva provided by MGI |
| **Official Full Name** | parvin, alpha provided by MGI |
| **Primary source** | MGI:MGI:1931144 |
| **See related** | Ensembl:ENSMUSG00000030770 |
| **Gene type** | protein coding |
| **RefSeq status** | VALIDATED |
| **Organism** | Mus musculus |
| **Lineage** | Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus |
| **Also known as** | 2010012A22Rik, 5430400F08Rik, AI225929, AU042898, Actp, CH-ILKBP, Parvin |
| **Expression** | Broad expression in bladder adult (RPKM 57.6), subcutaneous fat pad adult (RPKM 27.9) and 22 other tissues See more |
| **Orthologs** | human all |

# Transcript information（Ensembl）

The gene has 5 transcripts,all transcripts are shown below:

| Name | Transcript ID | bp | Protein | Biotype | CCDS | UniProt | Flags |
|---|---|---|---|---|---|---|---|
| Parva-201 | ENSMUST00000033030.13 | 4454 | 372aa | Protein coding | CCDS40091 | Q9EPC1 | TSL:1 GENCODE basic APPRIS is a system to annotate alternatively spliced transcripts based on a range of computational methods to identify the most functionally important transcript(s) of a gene. APPRIS P2 |
| Parva-203 | ENSMUST00000106643.7 | 2222 | 372aa | Protein coding | CCDS40091 | Q9EPC1 | TSL:1 GENCODE basic APPRIS is a system to annotate alternatively spliced transcripts based on a range of computational methods to identify the most functionally important transcript(s) of a gene. APPRIS P2 |
| Parva-202 | ENSMUST00000106640.1 | 1465 | 336aa | Protein coding | - | Q3UF75 | TSL:1 GENCODE basic APPRIS is a system to annotate alternatively spliced transcripts based on a range of computational methods to identify the most functionally important transcript(s) of a gene. APPRIS ALT2 |
| Parva-205 | ENSMUST00000139720.7 | 5869 | 66aa | Nonsense mediated decay | - | D6RHM9 | TSL:1 |
| Parva-204 | ENSMUST00000126047.1 | 354 | No protein | Processed transcript | - | - | TSL:5 |

The strategy is based on the design of *Parva-201* transcript,the transcription is shown below:



# Genomic location distribution



# Protein domain



# Mouse phenotype description(MGI )




*Phenotypes affected by the gene are marked in blue.Data quoted from MGI database(http://www.informatics.jax.org/).*

According to the existing MGI data,embryos homozygous for a null allele are growth retarded and die prior to E14.5 exhibiting abnormal cardiac morphogenesis, severe vascular defects, edema, microaneurysms, hemorrhage, and severe kidney dysgenesis or agenesis.

集萃药康
GemPharmatech

If you have any questions, you are welcome to inquire.

Tel: 400-9660890

集萃药康生物科技
GemPharmatech Co.,Ltd